Aileron Therapeutics Stock Forum

$Aileron Therapeutics (ALRN.US)$
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Aileron Therapeutics (NASDAQ: ALRN) is presenting data from its Phase 1b clinical trial of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis. The trial's Cohort 1, evaluating low-d...

$Aileron Therapeutics (ALRN.US)$ Aileron Therapeutics Completes Enrollment for Phase 1b IPF Drug Trial, Topline Data Expected Soon
Benzinga· 6 mins ago

$Aileron Therapeutics (ALRN.US)$
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics (NASDAQ: ALRN) has completed enrollment in Cohort 2of its ongoing Phase 1b clinical trial evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF). The trial, which enrolled a total of 24 patients, aims to assess the safety and tolerability of LTI-03 in IPF patients after 14 days of treatment...

$Aileron Therapeutics (ALRN.US)$
NEWS
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

$Aileron Therapeutics (ALRN.US)$
NEWS
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics, Inc. announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in IPF. Low-dose LTI-03 showed reductions in profibrotic proteins, increased expression of biomarkers, and was well-tolerated. Positive trends were observed in seven out of eight biomarkers. Data from Cohort 2 is expec...

$Aileron Therapeutics (ALRN.US)$ I will quietly take it!

$Aileron Therapeutics (ALRN.US)$ Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024

$Aileron Therapeutics (ALRN.US)$ 30% hmm